A meta-analysis of 285 studies found lifetime psychosis in over half of patients with bipolar disorder and comorbid schizophrenia in 8%, with substantial differences between bipolar I and bipolar II subtypes.

Anonymous survey data from 2,689 young U.S. and Canadian men found 95% reported using at least one strategy to force sex with a nonconsenting woman, with self-reported success in roughly two-thirds of attempts.

Algorithm-guided treatment was associated with improved remission rates in 5 of 7 randomized trials of major depressive disorder, though heterogeneity in protocols and outcome measures limited direct comparability.

A network meta-analysis of 24 antipsychotics across 78,193 patients with schizophrenia identified clozapine, amisulpride, olanzapine, and risperidone as most effective, with small-to-medium efficacy differences and notable variation in tolerability profiles.

Chronic PPI use was associated with elevated dementia and mild cognitive impairment risk in older adults across pooled observational studies, though high heterogeneity and residual confounding leave causality unresolved.

Viatris recalled one lot of Xanax XR 3-mg extended-release tablets after failed dissolution testing, with the FDA classifying the action as Class II and reporting no adverse events to date.